Skip to content

Member

Sirpa PIETIKÄINEN

EPP · Finland

Group
EPP PPE
Country
Finland
Roll-call participation
89.6 %ⓘ of 5 503 roll calls in office · chamber median 90.2 % · whole term, roll calls
With majority line
85.0 %ⓘ of 4 932 votes where the group had a line · EPP median 93.6 %
More facts (5)
National party
KOK Kansallinen Kokoomus
In office
Since 1 Dec 2024
Against clear line
664 of 4 722 votesⓘ
Committees
ECON, ENVI (substitute), FEMM, SANT (substitute)
Member id
40599
More

Record

The member’s figures against the median of their group and of the chamber. Each vote counts the member in the group they belonged to that day.

Roll-call participation ⓘ

89.6 %

4 932 of 5 503 roll calls while in office

EPP median: 89.9 % (−0.3 pts)

Chamber median: 90.2 %

With majority line ⓘ

85.0 %

4 194 of 4 932 votes where their group had a line

EPP median: 93.6 % (−8.6 pts)

Against clear line ⓘ

14.1 %

664 of 4 722 votes where their group had a clear line

610 opposite (for ↔ against), 44 abstained against the line, 10 voted for or against when the line was to abstain

Abstention ⓘ

1.1 %

55 of 4 932 votes cast

Participation 89.6 % — EPP median 89.9 %, 196 members.ⓘ
Data as a table
Participation among the 196 members of the EPP with enough votes.
FigureParticipation
Sirpa PIETIKÄINEN89.6 %
EPP median89.9 %
Lowest in the group17.0 %
Highest in the group99.6 %
Members196
With majority line 85.0 % — EPP median 93.6 %, 196 members.ⓘ
Data as a table
With majority line among the 196 members of the EPP with enough votes.
FigureWith majority line
Sirpa PIETIKÄINEN85.0 %
EPP median93.6 %
Lowest in the group70.2 %
Highest in the group99.5 %
Members196
  • Whole term, 5 928 roll-call votes. The dots are the other members of EPP; no ranks.
  • “No vote recorded” is not the same as absent: leave, illness and chairing the sitting look the same.
  • A group’s line is inferred from its members’ votes — Parliament publishes no whip.

Votes, 5 503

Export

Every roll-call vote of the term with the member’s position, newest first.

Result: for–against–abstained. Majority line: how most of the member’s group voted that day (“Tie” when no position won). ≠ group marks a vote otherwise than a clear line (at least two thirds, with at least 10 members voting) of their group.
DateDecision and voteResultPositionMajority line
20 Jan 2026The 28th Regime: a new legal framework for innovative companies Amendment 29, adding text after paragraph 10 135 for, 471 against, 52 abstainedPosition: Against Majority line: Against
20 Jan 2026The 28th Regime: a new legal framework for innovative companies Amendment 7 to paragraph 10 — part 2 103 for, 500 against, 61 abstainedPosition: Against Majority line: Against
20 Jan 2026The 28th Regime: a new legal framework for innovative companies Amendment 28, adding text after paragraph 2 190 for, 454 against, 16 abstainedPosition: Against Majority line: Against
20 Jan 2026The 28th Regime: a new legal framework for innovative companies Amendment 33 to paragraph 2 196 for, 446 against, 15 abstainedPosition: Against Majority line: Against
20 Jan 2026The 28th Regime: a new legal framework for innovative companies Amendment 3, adding text after paragraph 1 116 for, 489 against, 56 abstainedPosition: Against Majority line: Against
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Final votePassed 503 for, 57 against, 108 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 247, adding text after recital 22 224 for, 424 against, 20 abstainedPosition: Against Majority line: Against
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 256, adding text after recital 12 362 for, 259 against, 34 abstainedPosition: For ≠ groupMajority line: Against
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 259 to recital 4 197 for, 454 against, 7 abstainedPosition: Against Majority line: Against
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 244, adding text after recital 3 227 for, 299 against, 138 abstainedPosition: For ≠ groupMajority line: Against
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 187 to Article 23 527 for, 121 against, 15 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 178 to Article 22 529 for, 120 against, 16 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 170 to Article 21 525 for, 123 against, 14 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 250 to Article 16, after paragraph 2 141 for, 516 against, 7 abstainedPosition: Against Majority line: Against
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 257 to Article 3, paragraph 1, point 5 325 for, 284 against, 33 abstainedPosition: Against Majority line: Against
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 164 450 for, 205 against, 8 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 163 528 for, 123 against, 10 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 162 494 for, 152 against, 17 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 159 517 for, 127 against, 15 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Amendment 158 492 for, 159 against, 14 abstainedPosition: For Majority line: For
20 Jan 2026Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest Proposal to reject the text 44 for, 600 against, 13 abstainedPosition: Against Majority line: Against
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Final vote — text as a wholeAdopted 438 for, 37 against, 48 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Separate vote on recital H 455 for, 88 against, 11 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Paragraph 11 — part 2 431 for, 110 against, 11 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Paragraph 11 — part 1 472 for, 61 against, 24 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Amendment 2, adding text after paragraph 9 54 for, 483 against, 13 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Amendment 1, adding text after paragraph 9 86 for, 463 against, 8 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Separate vote on paragraph 9 429 for, 76 against, 51 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Paragraph 7 — part 2 441 for, 94 against, 23 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Paragraph 7 — part 1 451 for, 43 against, 65 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Continuous Belarusian hybrid attacks against Lithuania Amendment 3 to paragraph 4 385 for, 97 against, 78 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Decarbonisation and modernisation of EU fisheries, and the development and deployment of fishing gear Final vote — text as a wholeAdopted 450 for, 93 against, 37 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Decarbonisation and modernisation of EU fisheries, and the development and deployment of fishing gear Amendment 7, adding text after paragraph 77 219 for, 337 against, 24 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Decarbonisation and modernisation of EU fisheries, and the development and deployment of fishing gear Amendment 6 to paragraph 61 204 for, 359 against, 13 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Decarbonisation and modernisation of EU fisheries, and the development and deployment of fishing gear Amendment 5 to paragraph 46 227 for, 346 against, 8 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Decarbonisation and modernisation of EU fisheries, and the development and deployment of fishing gear Amendment 4 to paragraph 42 227 for, 348 against, 4 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Decarbonisation and modernisation of EU fisheries, and the development and deployment of fishing gear Amendment 3 to paragraph 8 196 for, 367 against, 19 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Decarbonisation and modernisation of EU fisheries, and the development and deployment of fishing gear Amendment 1 to paragraph 1 217 for, 365 against, 1 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Final vote — text as a wholeAdopted 386 for, 184 against, 15 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 6, adding text after recital G 189 for, 376 against, 13 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 5, adding text after recital G 187 for, 377 against, 16 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 4, adding text after recital F 181 for, 384 against, 13 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 3, adding text after recital C 197 for, 378 against, 7 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 1, adding text after recital B 200 for, 382 against, 2 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 17, adding text after paragraph 53 183 for, 388 against, 10 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 16, adding text after paragraph 49 170 for, 386 against, 28 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Separate vote on paragraph 40 414 for, 152 against, 20 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Implementation of the rule of law conditionality regime Separate vote on paragraph 39 411 for, 152 against, 20 abstainedPosition: No vote recorded Majority line: For
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 15, adding text after paragraph 20 179 for, 396 against, 9 abstainedPosition: No vote recorded Majority line: Against
18 Dec 2025Implementation of the rule of law conditionality regime Amendment 14, adding text after paragraph 18 199 for, 372 against, 4 abstainedPosition: No vote recorded Majority line: Against

Show all 50 votes on this page

Roll-call participation

One cell per sitting while in office, shaded by the share of that day’s roll calls the member voted in. The official attendance register is kept separately by Parliament.

No vote recorded on 31 of 88 sittings with roll calls.

"No vote recorded" is not the same as absent: leave, illness and chairing the sitting look the same.

Data as a table

Voting neighbours

Members who voted the same way most often in the roll calls they both took part in, within and outside the member’s group (group at the date of each vote), over all roll calls of the term.

At least 200 shared roll calls over at least six months in office together. Within = both sat in the same group on the date of the vote; a member who changed group can appear on both lists. Baseline = the median agreement of all pairs of members of the groups the two sat in on the date of each shared vote (within: the group they shared; outside: the two groups), weighted by the votes they shared in each combination.

Within EPP

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in the same group (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of that group.
SelectMemberGroupCountryAgreementBaseline
Willemien KONING EPPNetherlands87 % of 1 811 shared89 %
Aura SALLA EPPFinland87 % of 4 053 shared89 %
Axel VOSS EPPGermany86 % of 3 754 shared89 %
Isabel WISELER-LIMA EPPLuxembourg86 % of 4 796 shared89 %
Liesbet SOMMEN EPPBelgium86 % of 4 836 shared89 %
Marie-Sophie CHRIST EPPGermany86 % of 1 392 shared89 %
Manuela RIPA EPPGermany86 % of 4 456 shared89 %
Sandra KALNIETE EPPLatvia85 % of 4 619 shared89 %
Martine KEMP EPPLuxembourg85 % of 4 347 shared89 %
Verena MERTENS EPPGermany85 % of 4 277 shared89 %

Show all 10 neighbours

Outside the group

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in different groups (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of the groups the two sat in on those votes (groups at the date, weighted by the votes shared in each combination).
SelectMemberGroupCountryAgreementBaseline
Ľudovít ÓDOR RenewSlovakia89 % of 4 580 shared82 %
Yvan VEROUGSTRAETE RenewBelgium89 % of 3 540 shared82 %
Veronika CIFROVÁ OSTRIHOŇOVÁ RenewSlovakia88 % of 3 700 shared82 %
Martin HOJSÍK RenewSlovakia88 % of 4 419 shared82 %
Lucia YAR RenewSlovakia88 % of 4 880 shared82 %
Katarina BARLEY S&DGermany88 % of 3 672 shared75 %
Iratxe GARCÍA PÉREZ S&DSpain88 % of 4 627 shared75 %
Brigitte VAN DEN BERG RenewNetherlands88 % of 4 104 shared82 %
Michal WIEZIK RenewSlovakia88 % of 4 465 shared82 %
Dainius ŽALIMAS RenewLithuania88 % of 4 547 shared82 %

Show all 10 neighbours

Work

Seats in committees, delegations and intergroups, and the dossiers the member leads, shadows or negotiates.

Seats

Body: the committee, delegation or intergroup, with its kind. Role: the member’s role in it. From, To: the dates of the seat (“now” while it lasts).
BodyRoleFromTo
Committee on Economic and Monetary AffairsECON CommitteeMember16 Dec 2024now
Committee on the Environment, Climate and Food SafetyENVI CommitteeSubstitute20 Jan 2025now
Committee on Women’s Rights and Gender EqualityFEMM CommitteeMember16 Dec 2024now
Committee on Public HealthSANT CommitteeSubstitute23 Jan 2025now
Delegation for relations with the People's Republic of ChinaD-CN DelegationSubstitute2 Dec 2024now
Delegation for relations with the Pan-African ParliamentDPAP DelegationMember16 Dec 2024now
Intergroup on Cancer and Rare DiseasesIG10-05 Intergroup / working groupMember27 Jan 2025now
Intergroup on Children’s RightsIG10-06 Intergroup / working groupMember19 Feb 2025now
Intergroup on DisabilityIG10-10 Intergroup / working groupMember11 Mar 2025now
Intergroup on Fighting against PovertyIG10-12 Intergroup / working groupMember17 Jun 2025now

Show all 18 seats

Dossiers

Dossier: the procedure the declaration names (“No dossier named” for a delegation without one). Role: rapporteur, shadow rapporteur, negotiator or delegation. Committee: the committee that appointed them. Date: of the declaration.
DossierRoleCommitteeDate
Neurological health strategyShadow rapporteurSANT20 Jul 2026
Union Civil Protection Mechanism and Union support for health emergency preparedness and response, and repealing Decision No 1313/2013/EU (Union Civil Protection Mechanism)Shadow rapporteurSANT23 Apr 2026
Safety, resilience and sustainability of space activities in the UnionShadow rapporteur for an opinionENVI3 Nov 2025
Collection of statistical information by the European Central BankShadow rapporteurECON24 Sept 2025
Developing a new EU anti-poverty strategyShadow rapporteur for an opinionFEMM25 Jun 2025
Gender inequalities in health, specifically as regards gender-specific conditionsShadow rapporteur for an opinionSANT25 Jun 2025

Topics they work on (model-assigned)

Counts: dossiers they spoke on, led or amended, and their questions and motions.

In the chamber

Speeches and statements in plenary debates, newest first; the verbatim report is on Parliament’s site.

24 contributions recorded, 17 written statements; 12 minutes of speaking time.

Show all 24 recent contributions

Questions and motions, 75

Parliamentary questions and motions for resolutions the member authored or co-signed, newest first.

Date: tabled. Title: the question or motion, with its id. Kind: written question or motion for a resolution, with the number of co-authors. Answer: the date of the answer to a question.
DateTitleKindAnswer
8 Sept 2026Chatbots directing women with unwanted pregnancies to anti-abortion websites E-10-2026-003539Written questionwith 67 co-authorsNot yet answered
2 Sept 2026MOTION FOR A RESOLUTION on the draft Commission implementing decision renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87460 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B-10-2026-0381Motion for a resolutionwith 3 co-authors—
2 Sept 2026MOTION FOR A RESOLUTION on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean GMB151 x DAS-44406-6 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B-10-2026-0380Motion for a resolutionwith 3 co-authors—
2 Sept 2026MOTION FOR A RESOLUTION on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean MON 94313 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B-10-2026-0379Motion for a resolutionwith 3 co-authors—
16 Jul 2026Ensuring the continued operation of the Blue Flag Programme under Directive (EU) 2024/825 E-10-2026-003031Written questionwith 29 co-authors18 Sept 2026
8 Jul 2026Impact of the recent US Supreme Court ruling on the EU–US Data Privacy Framework and European data sovereignty E-10-2026-002823Written questionwith 21 co-authorsNot yet answered
1 Jul 2026MOTION FOR A RESOLUTION on the draft Commission implementing decision renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified soybean MON 87705 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B-10-2026-0334Motion for a resolutionwith 3 co-authors—
1 Jul 2026MOTION FOR A RESOLUTION on the draft Commission Implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize DP202216 x NK603 x DAS-40278-9 and its sub-combinations DP202216 x NK603, DP202216 x DAS-40278-9, pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B-10-2026-0336Motion for a resolutionwith 3 co-authors—
1 Jul 2026MOTION FOR A RESOLUTION on the Commission Implementing Decision renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified maize NK603 × T25 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B-10-2026-0335Motion for a resolutionwith 3 co-authors—
29 Jun 2026Scrutiny of hunting trophy imports into the EU E-10-2026-002689Written questionwith 8 co-authors25 Aug 2026

Show all 75 questions and motions

Amendments tabled in committee, 126

Committee amendment documents that carry amendments by the member, with how many are theirs.

Date: of the amendment document. Text amended: the dossier and the document’s id. Committee: where the amendments were tabled. Amendments: how many in the document are the member’s.
DateText amendedCommitteeAmendments
11 Sept 2026Modernised rules for patients’ rights in cross-border healthcare SANT-AM-792154 SANT21
11 Sept 2026Modernised rules for patients’ rights in cross-border healthcare SANT-AM-792014 SANT43
31 Jul 2026on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) No 1095/2010, No 648/2012, No 600/2014, No 909/2014, 2015/2365, 2019/1156, 2021/23, 2022/858, 2023/1114, No 1060/2009, 2016/1011, 2017/2402, 2023/2631 and 2024/3005 as regards the further development of capital market integration and supervision within the Union ECON-AM-791134 ECON9
31 Jul 2026on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) No 1095/2010, No 648/2012, No 600/2014, No 909/2014, 2015/2365, 2019/1156, 2021/23, 2022/858, 2023/1114, No 1060/2009, 2016/1011, 2017/2402, 2023/2631 and 2024/3005 as regards the further development of capital market integration and supervision within the Union ECON-AM-791136 ECON4
31 Jul 2026on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) No 1095/2010, No 648/2012, No 600/2014, No 909/2014, 2015/2365, 2019/1156, 2021/23, 2022/858, 2023/1114, No 1060/2009, 2016/1011, 2017/2402, 2023/2631 and 2024/3005 as regards the further development of capital market integration and supervision within the Union ECON-AM-791135 ECON39
31 Jul 2026on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) No 1095/2010, No 648/2012, No 600/2014, No 909/2014, 2015/2365, 2019/1156, 2021/23, 2022/858, 2023/1114, No 1060/2009, 2016/1011, 2017/2402, 2023/2631 and 2024/3005 as regards the further development of capital market integration and supervision within the Union ECON-AM-791103 ECON3
28 Jul 2026Amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and amending Regulation (EU) 2022/123 as regards the support of the European Medicines Agency for the expert panels on medical devices and Regulation (EU) 2024/1689 as regards the list of Union harmonisation legislation referred to in its Annex I SANT-AM-791887 SANT3
28 Jul 2026Amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and amending Regulation (EU) 2022/123 as regards the support of the European Medicines Agency for the expert panels on medical devices and Regulation (EU) 2024/1689 as regards the list of Union harmonisation legislation referred to in its Annex I SANT-AM-791891 SANT1
27 Jul 2026on the proposal for a directive of the European Parliament and of the Council amending Directives 2009/65/EC, 2011/61/EU and 2014/65/EU as regards the further development of capital market integration and supervision within the Union ECON-AM-791126 ECON1
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790953 CJ531

Show all 126 amendment documents

Connections

Dossiers they lead or shadow, committees, party, delegation and other related pages.

Political group

National delegation

  • Delegation Finland National delegation

Sources & citation

Where the facts on this page come from, and how to cite it.

Data source
Licensed CC BY 4.0.
Data version
data version 7669c786bb14 (1 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1 · methods
Retrieved
1 October 2026

Cite as

EU Parl Watch Research (2026). “Sirpa PIETIKÄINEN”. Member record. memberId 40599. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/members/40599?page=51&roles=all&vscope=all (retrieved 1 October 2026). Official source: Member’s profile, European Parliament, https://www.europarl.europa.eu/meps/en/40599. Data: EP Open Data: member record, https://data.europarl.europa.eu/api/v2/meps/40599?format=application%2Fld%2Bjson (CC BY 4.0); data version 7669c786bb14 (1 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1.
BibTeX
@misc{epw-member-40599,
  author = {{EU Parl Watch Research}},
  title = {{Sirpa PIETIKÄINEN}},
  year = {2026},
  howpublished = {\url{https://news.eu-parl.st-solutions.dev/members/40599?page=51&roles=all&vscope=all}},
  url = {https://news.eu-parl.st-solutions.dev/members/40599?page=51&roles=all&vscope=all},
  urldate = {2026-10-01},
  publisher = {EU Parl Watch Research},
  note = {Member record. memberId 40599. Official source: https://www.europarl.europa.eu/meps/en/40599. Data: EP Open Data: member record (CC BY 4.0); data version 7669c786bb14 (1 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1}
}